• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Post Conference Perspective: Immune Checkpoint Inhibitors in Advanced and Metastatic Urothelial Carcinoma

home / post-conference-perspectives / immune-checkpoint-inhibitors-in-advanced-and-metastatic-urothelial-carcinoma

Petros Grivas, MD, PhD, reviews emerging data from the 2021 ASCO GU Virtual Symposium on the role of immune checkpoint inhibitors for the treatment of advanced and metastatic urothelial carcinoma.

© 2023 MJH Life Sciences
All rights reserved.